Protalix BioTherapeutics, Inc. (PLX) Total liabilities 2016–2025
Protalix BioTherapeutics, Inc. (PLX) total liabilities at each fiscal year-end, per SEC filings.
$34.1MFY2025 · since FY2016: $92.2M → $34.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $34.1M | +12.9% |
| FY2024 | $30.2M | -40.6% |
| FY2023 | $50.9M | -23.4% |
| FY2022 | $66.4M | -16.7% |
| FY2021 | $79.7M | -16.1% |
| FY2020 | $95.0M | -17.9% |
| FY2019 | $115.7M | +1.5% |
| FY2018 | $114.0M | +12.1% |
| FY2017 | $101.7M | +10.3% |
| FY2016 | $92.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice